73 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
8 Aug 19
Zafgen Reports Second Quarter 2019 Operating and Financial Results
4:32pm
of 2019
PATH for PWS study over-enrolled with continued strong support from Prader-Willi syndrome (PWS) community
Boston, August 8, 2019 – Zafgen, Inc … and other important segments of the PWS community, versus the initial goal of 500 participants. The data from this study are intended to inform
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
7 Nov 18
Zafgen Reports Third Quarter 2018 Operating and Financial Results
4:15pm
MetAP2 inhibitor,ZGN-1345, to development candidate status. Further, the resurgence of our active engagement with the Prader-Willi community … and engagement from the PWS community around this initiative, and enrollment has been robust since opening, with approximately 190 of the500-participant
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
development for the FA community. I am very excited to devote my full effort and attention towards the continued development of CTI-1601 and look
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
, patient community and financial goals.”
As of June 6, 2018, the Zafgen Board of Directors includes:
Peter Barrett, Ph.D., Chairman, Partner
8-K
EX-99.3
LRMR
Larimar Therapeutics Inc
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
program are expected by the end of 2020.
“On behalf of FARA and the FA community, we are grateful to the Chondrial team for their hard work and dedication
8-K
EX-10.1
tt01kwa54f
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
DEFA14A
EX-99.3
62lfgtjn gfyx
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
sbqafngl jim1
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
uf8z69icpyo
9 May 19
Zafgen Reports First Quarter 2019 Operating and Financial Results
4:26pm
8-K
EX-10.2
hxyt1ben
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
8-K
EX-99.1
b8ligyz
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
2wfebf3
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
vx43k 3b4
11 May 21
Other Events
8:34am
8-K
EX-99.1
5vj lwtgf51b8q8
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
10-K/A
c2pb2k7rv6ulxlzyn
29 Apr 16
Annual report (amended)
12:00am
S-1
EX-10.1
y785g24a9xvy59rkjw
18 Apr 14
IPO registration
12:00am